Back to top
more

Amphastar Pharmaceuticals (AMPH)

(Delayed Data from NSDQ)

$42.02 USD

42.02
342,556

+0.91 (2.21%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $42.06 +0.04 (0.10%) 5:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

Is Amphastar (AMPH) a Solid Growth Stock? 3 Reasons to Think "Yes"

Amphastar (AMPH) could produce exceptional returns because of its solid growth attributes.

Cigna (CI) Unit Ties Up to Offer Digital Health Tool to Clients

Cigna's (CI) division, Cigna Healthcare, teams up with Virgin Pulse to make an effective digital health solution available to its clients, who can now improve their well-being.

Sundeep Ganoria  headshot

3 Generic Drug Stocks to Watch Amid Improving Market Prospects

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to AMPH, RDY and TEVA.

Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?

Here is how Amphastar Pharmaceuticals (AMPH) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Dr. Reddy's Laboratories Ltd (RDY) Hits Fresh High: Is There Still Room to Run?

Doctor Reddy's (RDY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of 14.04% and 6.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

TEVA Q2 Earnings & Sales Top as Austedo Outperforms, Stock Up

TEVA's second-quarter results were strong as it beat estimates for earnings as well sales.

BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -13.95% and 65.14%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Dr. Reddy's (RDY) Q1 Earnings and Revenues Beat Estimates

Dr. Reddy's (RDY) reports better-than-expected fiscal first-quarter 2024 results.

Amphastar Pharmaceuticals (AMPH) Dips More Than Broader Markets: What You Should Know

Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $61.38, moving -0.44% from the previous trading session.

Amphastar Pharmaceuticals (AMPH) is a Great Momentum Stock: Should You Buy?

Does Amphastar Pharmaceuticals (AMPH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Amphastar (AMPH) to Report Q2 Earnings: What's in the Cards?

Amphastar's (AMPH) revenues in the second quarter of 2023 are expected to have been driven by the sales of its high-margin pharmaceutical products.

Amphastar Pharmaceuticals (AMPH) Gains As Market Dips: What You Should Know

Amphastar Pharmaceuticals (AMPH) closed at $63.25 in the latest trading session, marking a +1.48% move from the prior day.

The Zacks Analyst Blog Highlights Abercrombie & Fitch, InterDigital, Shake Shack, Amphastar and PGT Innovations

Abercrombie & Fitch, InterDigital, Shake Shack, Amphastar and PGT Innovations are included in this Analyst Blog.

Nalak Das headshot

5 Must-Buy High-Flying Mid-Caps to Enhance Your Portfolio

We have narrowed our search to five mid-cap stocks with more than 50% returns year to date. These are: PGTI, SHAK, IDCC, ANF, AMPH.

BridgeBio Pharma (BBIO) Moves 75.9% Higher: Will This Strength Last?

BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Amphastar Pharmaceuticals (AMPH) Gains As Market Dips: What You Should Know

Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $55.87, moving +1.07% from the previous trading session.

Here's Why Investors Should Add Encompass Health (EHC) to Portfolio

Encompass Health (EHC) remains well-poised for growth on the back of solid demand for effective inpatient rehabilitation services, joint ventures and solid cash reserves.

Amphastar (AMPH) is an Incredible Growth Stock: 3 Reasons Why

Amphastar (AMPH) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?

Here is how Align Technology (ALGN) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.

Zacks.com featured highlights include PDD Holdings, Amphastar Pharmaceuticals and Suzano

PDD Holdings, Amphastar Pharmaceuticals and Suzano are part of the Zacks Screen of the Week article.

Tirthankar Chakraborty headshot

3 Profitable Stocks Worth Investing in Using Net Income Ratio

PDD Holdings (PDD), Amphastar Pharmaceuticals (AMPH) and Suzano (SUZ) are some of the top picks with a high net income ratio.

Amphastar Pharmaceuticals (AMPH) Is Up 0.54% in One Week: What You Should Know

Does Amphastar Pharmaceuticals (AMPH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Factors That Make HCA Healthcare (HCA) a Lucrative Bet Now

HCA Healthcare (HCA) remains well-poised for growth on the resumption of elective surgeries, acquisitions and strong cash-generation abilities.

3 Reasons Growth Investors Will Love Amphastar (AMPH)

Amphastar (AMPH) is well positioned to outperform the market, as it exhibits above-average growth in financials.